Systemic Lupus Erythematosus Treatment Global Market Report 2024

The systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to several factors, including significant advancements in biologics and targeted therapies designed for treating systemic lupus erythematosus (SLE), a heightened understanding of the disease mechanisms, extensive clinical trials and research initiatives focusing on lupus treatments, governmental initiatives aimed at addressing rare disease treatments including lupus, and increased awareness and improved diagnostic capabilities leading to more cases being identified and diagnosed.

The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the forecast period can be linked to several factors, including the emergence of biosimilars tailored for treating systemic lupus erythematosus (SLE), the incorporation of digital health solutions into lupus management, an increased focus on complementary and alternative medicine in lupus care, ongoing innovations in immunomodulatory therapies, and the proactive role of patient advocacy and support organizations. Key trends expected in this period encompass the utilization of combinatorial therapies for SLE, personalized medicine approaches catering to individual patient needs, the increasing use of biosimilars in treating lupus, the integration of telemedicine into SLE management practices, educational initiatives aimed at empowering lupus patients, and a rise in global collaborations fostering research dedicated to lupus treatment and management.

The anticipated surge in autoimmune disorders is set to drive the expansion of the systemic lupus erythematosus treatment market. Autoimmune diseases manifest when the immune system erroneously attacks the body's own tissues, releasing autoantibodies that target healthy cells. Systemic lupus erythematosus, a prominent autoimmune disease, leads to widespread inflammation and tissue damage in affected organs, including joints, skin, brain, lungs, kidneys, and blood vessels. As of May 2023, the University of Oxford reveals that autoimmune disorders impact 10% of the global population, affecting 13% of women and 7% of men. Similarly, data from October 2021, shared by the City, University of London, indicates that approximately 4 million people in the UK, constituting 7% of the population, are estimated to have at least one autoimmune disease. With over 80 identified autoimmune disorders and an annual increase in prevalence by 3-9%, the escalating incidence of autoimmune disorders is a key driver for the systemic lupus erythematosus treatment market.

The projected growth of the systemic lupus erythematosus treatment market is further fueled by the escalating healthcare expenditure. Healthcare expenditure encompasses the total monetary outlay on healthcare services, goods, and associated activities within a specific healthcare system or economy over a defined period. This financial support creates a robust ecosystem for systemic lupus erythematosus treatment by facilitating research, development, access to innovative therapies, extensive clinical trials, and overall enhancements in patient care and outcomes. Notably, in May 2023, the UK's Office for National Statistics reports a nominal increase of 9.4% and a practical increase of 9.7% in healthcare spending. The total healthcare cost in the UK for 2021 reached $367.25 billion (£280.7 billion), with pharmaceutical costs amounting to $51.84 billion (£39.6 billion). A significant rise in preventative care spending, reaching $45.93 billion (£35.1 billion), underscores the pivotal role of increasing healthcare expenditure in propelling the systemic lupus erythematosus treatment market.

Prominent companies within the systemic lupus erythematosus treatment market are strategically concentrating on securing product approvals, exemplified by Saphnelo, to boost their market revenues. Saphnelo (anifrolumab-fnia) stands as a prescription medicine tailored for adults with systemic lupus erythematosus (SLE) ranging from moderate to severe, who concurrently use other lupus medications. A milestone achievement occurred in August 2021 when AstraZeneca PLC, a Sweden-based pharmaceutical giant, obtained FDA approval for anifrolumab-fnia (Saphnelo). This marked a groundbreaking development as it became the first FDA-approved type I interferon (type I IFN) receptor antagonist. Given the pivotal role of type I interferon signaling in the pathophysiology of lupus, with higher levels associated with more active and severe disease, Saphnelo's approval represents a significant stride in the systemic lupus erythematosus treatment landscape.

Major players in the systemic lupus erythematosus treatment market are strategically pursuing product approvals, with a notable example being Zynrelef (HTX-011), to drive market revenues. Zynrelef, a dual-acting, extended-release local anesthetic comprising bupivacaine and meloxicam, is designed to manage postoperative pain for up to 72 hours. Heron Therapeutics, Inc., a US-based biotechnology company, achieved a significant milestone in May 2021 with the FDA approval of Zynrelef (HTX-011). The medication is recommended for postoperative analgesia up to 72 hours following specific surgical procedures, including foot and ankle, small-to-medium open abdomen, and lower extremity total joint arthroplasty. Clinically proven to substantially reduce opioid usage after surgery and effectively control pain over a 72-hour period, Zynrelef outperforms the standard of care bupivacaine HCl solution, reinforcing its strategic significance in driving revenue growth within the systemic lupus erythematosus treatment market.

In March 2021, Merck, a pharmaceutical company based in the United States, completed the acquisition of Pandion Therapeutics for a total sum of $1.85 billion. This strategic acquisition provided Merck with access to Pandion Therapeutics' TALON technology, a valuable asset aimed at addressing unmet needs in autoimmune conditions by rebalancing the immune response. Pandion Therapeutics, a biotechnology company based in the United States, specializes in the development of innovative therapeutics. The primary focus of the company is on its lead candidate, PT101, which is an engineered IL-2 mutein combined with a protein backbone. PT101 is designed to effectively treat autoimmune diseases, including ulcerative colitis and systemic lupus erythematosus, by activating and expanding Tregs (regulatory T cells).

Major companies operating in the systemic lupus erythematosus treatment market report are GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., Anthera Pharmaceuticals Inc., AstraZeneca plc, Bristol-Myers Squibb Company Inc., F. Hoffmann-La Roche Ltd., ImmuPharma plc, Sanofi SA, Eli Lilly and Company, Amgen Inc., Johnson & Johnson Services Inc., Lycera Corporation, Roche Holding AG, Bayer AG, Novartis International AG, Viatris Inc., Swedish Orphan Biovitrum AB, Union Chimique Belge SA, Biogen Inc., Horizon Therapeutics plc, Gilead Sciences Inc., Daiichi Sankyo Company Limited, EMD Serono Inc., Hoth Therapeutics Inc., Zylo Therapeutics Inc., Kyowa Kirin Co. Ltd., Priothera Ltd., Centessa Pharmaceuticals plc, AbbVie Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited.

North America was the largest region in the systemic lupus erythematosus treatment market in 2023. The regions covered in the systemic lupus erythematosus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic lupus erythematosus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main categories of drugs used in treating systemic lupus erythematosus include antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive drugs. Antimalarial medications such as hydroxychloroquine (Plaquenil), chloroquine (Aralen), and quinacrine (Atabrine) have shown efficacy in managing lupus symptoms. These drugs are administered through various routes including subcutaneous, oral, and intravenous methods. Treatments for SLE are available through diverse channels including hospital pharmacies, retail pharmacies, and online sales.

The systemic lupus erythematosus treatment market research report is one of a series of new reports that provides systemic lupus erythematosus treatment market statistics, including systemic lupus erythematosus treatment industry global market size, regional shares, competitors with a systemic lupus erythematosus treatment market share, detailed systemic lupus erythematosus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the systemic lupus erythematosus treatment industry. This systemic lupus erythematosus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.